Info
l-mind
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
- At a median follow-up of 13.2 months, the
- objective response rate (ORR) was 60% (48/80 patients, efficacy set),
- complete response (CR) rate was 43% (34/80 patients),
- partial response (PR) rate was 18% (14/80 patients).
Cyclea Tafasitamab dosing schedule10,11 Lenalidomide dosing schedule in L-MIND9 Cycle 1 Days 1, 4, 8, 15, and 22 Days 1-21 Cycles 2 and 3 Days 1, 8, 15, and 22 Days 1-21 Cycles 4 to 12 Days 1 and 15 Days 1-21
Information
- Design: Phase 2, open-label, single-arm trial
- Number of patients: 81
- Patients characteristics: Patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation
- Agent: Tafasitamab (MOR208) plus lenalidomide
- Treatment line: Second-line therapy or later
- Trial Name or NCT Number: L-MIND (NCT02399085)
Results
- Primary endpoint: Objective response rate (ORR)
- Response rate: 60% (95% CI, 48-71)
- Complete response rate: 43% (95% CI, 32-54)
- Partial response rate: 18% (95% CI, 10-28)
Other findings
- Safety: The most common treatment-emergent adverse events of grade 3 or worse were neutropenia (48%), thrombocytopenia (17%), and febrile neutropenia (12%)
- Serious adverse events: 51% of patients experienced a serious adverse event, with the most frequent being pneumonia, febrile neutropenia, pulmonary embolism, bronchitis, atrial fibrillation, and congestive cardiac failure
Summary The L-MIND trial demonstrates that tafasitamab plus lenalidomide is a well-tolerated and effective treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem-cell transplantation, with a high response rate and complete response rate.